CLClinicLens

Unclassified

[Correspondence] Power, dose, and fosfomycin in the SCOUT trial | ClinicLens

In the SCOUT trial, Carl Llor and colleagues compared single-dose fosfomycin with three active comparators in 768 women with uncomplicated cystitis.1 The headline conclusion that fosfomycin's first-line role “should be re-evaluated” outruns the data on three counts.

Medical Literature · Updated

← Back to articles
This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.